MCPIP1 inhibits polyubiquitination of death receptor 5 (DR5) through its deubiquitinating enzyme activity, which then enhances the lysosomal degradation of DR5, leading to resistance to DR5 activation or TRAIL‐induced apoptosis in cancer cells [36]. Here, TNFRSF10B is linked to cancer.